Pharmaceuticals

T Cell Specific Surface Glycoprotein CD28 Industry Growth Insights: Revenue Forecast to 2030

February 18, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the t cell specific surface glycoprotein cd28 market from 2026–2035 with trusted insights from The Business Research Company

How is the T Cell Specific Surface Glycoprotein CD28 Market size predicted to change over the forecast window of 2026–2035?

The t cell specific surface glycoprotein cd28 market size has demonstrated robust expansion in recent years. It is anticipated to increase from $1.62 billion in 2025 to $1.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.0%. This growth during the historic period can be attributed to the early identification of cd28 as a t-cell co-stimulatory receptor, an increase in immunology research, the growing prevalence of autoimmune diseases, rising initiatives in cancer research, and the limited availability of monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. Key drivers for this growth during the forecast period include the advancement of lulizumab pegol and new cd28 inhibitors, an increase in preclinical and clinical studies, the incorporation of cd28-targeted treatments into autoimmune and cancer therapies, increased investment in biopharmaceutical research, and progress in immunomodulation and monoclonal antibody engineering. Significant trends expected over the forecast period encompass a greater embrace of flow cytometry and ELISA technologies, an increase in immunology and cancer research applications, the ongoing development of new cd28 inhibitors and biobetters, broadened research into stem cell and autoimmune diseases, and the inclusion of lulizumab pegol in preclinical and clinical investigations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Which Drivers Are Contributing To The Expansion Of The T Cell Specific Surface Glycoprotein CD28 Market?

The rising focus on personalized medicine is anticipated to fuel the expansion of the T cell-specific surface glycoprotein CD28 market in the future. Personalized medicine represents a medical strategy focused on customizing treatments for individual patients, taking into account their unique genetic makeup, environmental influences, and lifestyle, with the aim of maximizing therapeutic results and enhancing overall patient care. Demand for personalized medicine is on the rise, driven by progress in genomic technologies that facilitate accurate detection of genetic variations, leading to more customized treatments. T cell-specific surface glycoprotein CD28 contributes to personalized medicine by allowing for targeted immune system adjustments, thus making therapies more exact and potent. It improves therapeutic results through fostering optimal activation of T cells, thereby enhancing immune responses tailored to individual patients. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit, revealed that the U.S. Food and Drug Administration (FDA) granted approval to 26 new personalized medicines during 2023, marking an increase from the 12 approvals seen in 2022. Consequently, the increasing focus on personalized medicine is fueling the expansion of the T cell-specific surface glycoprotein CD28 market.

What Segment Classifications Make Up The T Cell Specific Surface Glycoprotein CD28 Market?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What Trends Are Projected To Support The Growth Of The T Cell Specific Surface Glycoprotein CD28 Market?

Major companies operating in the T cell-specific surface glycoprotein CD28 market are focusing on developing innovative products, such as combination immunotherapies, to enhance T cell activation, anti-tumor efficacy, and patient treatment outcomes. Combination immunotherapies are treatments that combine multiple immune-based approaches to boost the body’s ability to fight disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, released preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody for advanced bladder cancer. This compound is engineered to selectively activate CD28 on T cells upon binding to Nectin-4-expressing tumor cells, enhancing T-cell-mediated tumor killing while minimizing off-target toxicity. The data demonstrated potent anti-tumor activity in preclinical models, supporting further development as a potential therapy for patients with metastatic urothelial carcinoma.

Which Key Market Players Are Investing In Expansion And Innovation Within The T Cell Specific Surface Glycoprotein CD28 Market?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Regions Are Poised For Strategic Growth In The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized T Cell Specific Surface Glycoprotein CD28 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2026, By The Business Research Company

Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Display Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report

Holter Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795